Table 2.
Vaccination schedule for adults: a perspective on the chronic respiratory patient.
| Vaccine | Recommendation | Health agencies and authorities supporting the recommendation |
|---|---|---|
| Influenza | 1 dose of influenza vaccine during the annual campaign | GOLD31, GeSEPOC32, GINA33, CDC34 |
| Pneumococcus | 1 dose of PCV followed by 1 dose of PPSV23, with a minimum interval of 8 weeks. | CDCa,38 |
| PCV13 and PPSV23 from the age of 65 and PPSV23 also recommended in younger chronic respiratory patients with other co-morbidities | GOLD31 | |
| 1 dose of PCV13 | GesCOPD32 | |
| Bordetella pertussis | 1 booster dose every 10 years with dTpa in adults who have not previously received a dose of this vaccine | GOLD31, CDC53 |
| Consider dTpa | GesCOPD32 | |
| Herpes zoster | 2 doses of HZ/su starting at age 50 | GOLD31, CDC61 |
| SARS-CoV-2 coronavirus | Recommended depending on the evolution of the pandemic and the recommendations of the various governing bodies | |
a
Given the availability of 15- and 20-serotype pneumococcal conjugate vaccines in the United States, the current recommendation is to administer 1 dose of PCV15 or PCV20 to adult chronic respiratory patients. If PCV15 is administered, the recommendation is that a dose of PPSV23 should be administered at least one year later; whereas, if PCV20 is administered, subsequent vaccination with PPSV23 would not be recommended.